Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vaccine Manufacturing Hub Will Help UK Meet Coronavirus Challenge

Will Work With Oxford And AstraZeneca On Fast-Tracked Candidate

Executive Summary

Vaccine manufacturing capacity has been lost in the UK in recent decades. Now a new Vaccines Manufacturing Innovation Centre will re-seed that capacity and expertise - and the pandemic is accelerating its arrival.

You may also be interested in...



Coronavirus Update: AZ Gets $1bn From US, Secures Capacity For One Billion Vaccine Doses

Inovio vaccine data published, US government invests to protect, generic remdesivir launched in Bangladesh.

Pfizer Chief Calls Patent Pool ‘Nonsense’, Fears Tussle Over Vaccine

Pharma will oppose a patent pool, but the world still needs a way to guarantee fair access to COVID-19 vaccines.

Latecomer Merck Enters Coronavirus Vaccine Field With Themis Acquisition

While Moderna and others frontrunners aim for a 2020 emergency use approval, Merck believes a more deliberate approach will pay off in the long term.

Topics

Related Companies

UsernamePublicRestriction

Register

LL1132066

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel